Salarius Pharmaceuticals to be Acquired by Big Rock Partners
Ticker: DCOY · Form: 8-K · Filed: Jul 23, 2024 · CIK: 1615219
Sentiment: neutral
Topics: acquisition, merger, definitive-agreement
TL;DR
Salarius Pharma is getting bought by Big Rock Partners, deal expected Q4 2024.
AI Summary
Salarius Pharmaceuticals, Inc. announced on July 22, 2024, that it has entered into a definitive agreement to be acquired by Big Rock Partners, LLC. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions. This acquisition marks a significant event for Salarius Pharmaceuticals, as it transitions from its current operational status.
Why It Matters
This acquisition signifies a major change in control and operational direction for Salarius Pharmaceuticals, potentially impacting its ongoing research and development efforts and shareholder value.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions, and the success of the integration and future strategy under new ownership introduces inherent risks.
Key Players & Entities
- Salarius Pharmaceuticals, Inc. (company) — Company filing the 8-K and being acquired
- Big Rock Partners, LLC (company) — Acquiring entity
- July 22, 2024 (date) — Date of the definitive agreement
- Fourth quarter of 2024 (date) — Expected closing period for the acquisition
FAQ
What is the nature of the definitive agreement between Salarius Pharmaceuticals and Big Rock Partners?
Salarius Pharmaceuticals, Inc. entered into a definitive agreement to be acquired by Big Rock Partners, LLC.
When is the acquisition expected to be completed?
The transaction is expected to close in the fourth quarter of 2024.
What are the conditions for the closing of the acquisition?
The acquisition is subject to customary closing conditions.
What was Salarius Pharmaceuticals' former company name?
Salarius Pharmaceuticals, Inc.'s former company name was Flex Pharma, Inc., with a date of name change on July 30, 2014.
What is the principal executive office address for Salarius Pharmaceuticals?
The address of Salarius Pharmaceuticals' principal executive offices is 2450 Holcombe Blvd. Suite X, Houston, TX 77021.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-07-22 17:39:28
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 SLRX The Nasdaq Capital Market Indi
- $810,973 — vering the registered offering of up to $810,973 of shares of common stock, par value $0
Filing Documents
- flks-20240722.htm (8-K) — 29KB
- image_0.jpg (GRAPHIC) — 27KB
- slrx-ex51opiniontoprospect.htm (EX-5.1) — 15KB
- 0001615219-24-000062.txt ( ) — 207KB
- flks-20240722.xsd (EX-101.SCH) — 2KB
- flks-20240722_lab.xml (EX-101.LAB) — 22KB
- flks-20240722_pre.xml (EX-101.PRE) — 13KB
- flks-20240722_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On July 22, 2024, Salarius Pharmaceuticals, Inc. (the "Company") filed a prospectus supplement (the "Prospectus Supplement") to its effective registration statement on Form S-3 (File No. 333-266589) (the "Registration Statement"), filed with the U.S. Securities and Exchange Commission on August 5, 2022 and declared effective by the SEC on August 16, 2022, covering the registered offering of up to $810,973 of shares of common stock, par value $0.0001 per share, of the Company (the "Shares"), pursuant to the At the Market Offering Agreement, dated as of February 5, 2021, with Ladenburg Thalmann & Co. Inc. In connection with the filing of the Prospectus Supplement, the Company is filing a legal opinion of its counsel, Hogan Lovells US LLP, relating to the validity of the Shares being registered, which opinion is attached as Exhibit 5.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Hogan Lovells US LLP 23.1 Consent of Hogan Lovells US LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SALARIUS PHARMACEUTICALS, INC. Date: July 22, 2024 By: /s/ Mark J. Rosenblum Mark J. Rosenblum Chief Financial Officer